
Dec 15 (Reuters) - Redhill Biopharma Ltd 2RHy.F:
REDHILL BIOPHARMA'S POSITIVE OPAGANIB RESULTS INDICATE REDUCTION IN VENETOCLAX RESISTANT CELLS
REDHILL BIOPHARMA: IN VIVO RESULTS INDICATE OPAGANIB WITH VENETOCLAX REDUCES CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY HALF COMPARED TO CONTROLS
Further company coverage: [2RHy.F]